College of American Pathologists (CAP) Guidelines: Ensuring Quality and Accuracy in Pathology

The College of American Pathologists (CAP) plays a vital role in establishing and maintaining high standards in pathology and laboratory medicine. Through the development and dissemination of evidence-based guidelines, the CAP aims to improve diagnostic accuracy, ensure optimal patient care, and promote the consistent application of laboratory practices. These guidelines are developed meticulously, with a focus on transparency, conflict of interest management, and continuous review to stay current with evolving medical knowledge.

The Rigorous Development Process of CAP Guidelines

CAP guidelines are not created in a vacuum. The CAP employs a rigorous and transparent process to ensure their integrity and relevance. This process involves several key steps:

Systematic Literature Review: A thorough review of published medical literature is conducted, adhering to guideline development best practices. This ensures that recommendations are grounded in the latest scientific evidence.
Expert Panel Composition: Panels are composed of leaders in their respective fields, balancing subject matter expertise with measures to avoid conflicts of interest. A majority of the panel is free from conflicts of interest.
Open Comment Period: Draft recommendations are made available for public review and comment, allowing for a broad range of perspectives to be considered. The panel considers all comments during finalization of the recommendations.
Independent Review: An independent review process is used for guideline and guideline revision approval.

Scope and Application of CAP Guidelines

CAP guidelines address a wide range of topics relevant to pathology and laboratory medicine. These include, but are not limited to:

Cancer Reporting: The CAP Cancer Protocols provide guidelines for collecting essential data elements for complete reporting of malignant tumors and optimal patient care. These protocols assist pathologists in reporting relevant information and include tumor staging data used with permission of the American Joint Committee on Cancer (AJCC).
Immunohistochemistry (IHC) Assay Validation: CAP guidelines offer specific recommendations for the validation and verification of IHC assays, particularly for predictive markers. This is crucial for ensuring the accuracy and reliability of IHC testing, which plays a critical role in cancer diagnosis and treatment.

Key Considerations in IHC Assay Validation: An In-Depth Look

Immunohistochemistry (IHC) is a vital technique in pathology, used to identify specific proteins within tissue samples. Accurate and reliable IHC results are essential for diagnosis, prognosis, and treatment decisions. CAP guidelines provide detailed recommendations for validating and verifying IHC assays to ensure their performance characteristics meet the required standards.

Harmonization of Validation Requirements for Predictive Markers

The original CAP guideline outlined distinct requirements for validation/verification of HER2, ER, PR predictive markers. The updated guideline harmonizes validation requirements for all predictive markers. This means that regardless of the specific marker being assessed (e.g., HER2, ER, PR, PD-L1), the validation process follows a standardized approach.

Validation/Verification of IHC Assays with Separate Scoring Systems

Recommendation 6 provides validation/verification recommendations for IHC assays that have separate scoring systems employed depending on tumor site and/or clinical indication (eg, human epidermal growth receptor 2 [HER2], which has different scoring systems depending on tumor site, and programmed death receptor-1 [PD-L1], which employs different scoring systems based on tumor site and/or tumor type). The recommendation stipulates that laboratories should separately validate/verify each assay-scoring system combination. This is particularly relevant for markers like HER2 and PD-L1, where the interpretation of IHC results can vary depending on the specific type of cancer being assessed.

Validation of IHC on Cytology Specimens

Since the publication of the original guideline, laboratories have frequently requested more definitive validation guidelines for IHC performed on cytology specimens that are not fixed identically to those tissues used for initial assay validation. Based on this feedback and literature published since the initial guideline, conditional recommendation 9 and statement 10 require that laboratories perform separate validations with a minimum of 10 positive and 10 negative cases for IHC performed on specimens fixed in alternative fixatives. The guideline panel recognize that these new recommendations will impose an added burden to laboratories; however, the literature has shown variable sensitivity of IHC assays performed on specimens collected in fixatives often used in cytology laboratories compared with formalin-fixed, paraffin embedded (FFPE) tissues.

The CAP recognizes that cytology specimens, due to their unique preparation and fixation methods, may require separate validation studies. Conditional recommendation 9 and statement 10 address this issue, requiring laboratories to perform separate validations with a minimum of 10 positive and 10 negative cases for IHC performed on specimens fixed in alternative fixatives. This acknowledges the potential for variable sensitivity of IHC assays on cytology specimens compared to formalin-fixed, paraffin-embedded (FFPE) tissues.

Comparators for Validation/Verification Study Design

Statement 1 provides for many different comparators as models for validation/verification study design. These options are provided as part of this statement because most IHC assays do not have an applicable gold standard suitable for determining the performance characteristics of the new assay. As guidance, the following list is ordered from the most stringent to the least stringent comparator.

Comparing the new assay’s results to IHC results from cell lines that contain known amounts of protein (“calibrators”).
Comparing the new assay’s results with results of a non-immunohistochemical method, such as flow cytometry or fluorescent in-situ hybridization.
Comparing the new assay’s results with the results of testing the same tissues in another laboratory using a validated/verified assay.
Comparing the new assay’s results with the results of prior testing of the same tissues with a validated/verified assay in the same laboratory.
Comparing the new assay’s results with the results from testing the same tissues in a laboratory that performed testing for a clinical trial.

The CAP guideline provides several options for comparators in validation/verification study designs, recognizing that a definitive gold standard may not always be available for IHC assays. These comparators range from the most stringent (e.g., comparison to cell lines with known protein amounts) to less stringent (e.g., comparison to prior testing in the same laboratory).

Read also: Phoenix Suns' New Center

Important Considerations and Caveats

While CAP guidelines provide valuable recommendations, it's crucial to understand their limitations and appropriate use:

Not Mandatory: As with any clinical evidence-based guidelines, laboratories are not required to follow the recommendations.
Not Always Aligned with Accreditation Checklists: Some recommendations may not align with the 2023 Laboratory Accreditation Program (LAP) Checklist. While these recommendations may be incorporated into future versions of the CAP Laboratory Accreditation Program (LAP) Checklist; the major changes to this guideline are not currently required by LAP or any regulatory/accrediting agency.
Prospective Application: Although this guideline prospectively applies to new assays used on patient specimens, The Clinical Laboratory Improvement Amendments of 1988 (CLIA), and by extension, CAP LAP, requires laboratories to validate/verify the performance characteristics of all assays before issuing results on patient specimens. Thus, even if an assay has been in clinical use, the lack of documentation of a previous analytic validation may result in a citation by an accrediting agency. It is NOT the intention of the new statements 9 and 10 to mandate revalidation of all IHC assays that are currently performed on cytology specimens. However, as stipulated in the original guideline, some sort of validation study should have been performed on cytology specimens whose tissues were not fixed in the same manner as the tissues used for original assay validation.
Validation and Quality Management Plans: Assessment of these two variables is not explicitly included in the updated guideline. However, it would be wise for IHC laboratory medical directors to design both a validation plan and a quality management plan that evaluate these two variables. A reasonable strategy might include running the validation set on different instruments over a period of a few days. Each of these runs should be performed by a different laboratory personnel.
Copyright Restrictions: The College of American Pathologists (CAP) does not permit reproduction of any substantial portion of these protocols without its written authorization. The CAP hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. The Protocols include tumor staging data used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The CAP developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the CAP recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the required data elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with these documents.

Laboratories are not mandated to follow CAP guidelines, and some recommendations may not be fully aligned with accreditation checklists. The guidelines primarily apply to new assays, but existing assays still require validation under CLIA regulations. It is crucial for laboratories to develop comprehensive validation and quality management plans, considering factors like instrument variation and personnel performance.

The Importance of Adherence and Continuous Improvement

While not mandatory, adherence to CAP guidelines is highly recommended. These guidelines represent a consensus of expert opinion and are based on the best available scientific evidence. Following these guidelines can help laboratories:

Improve Diagnostic Accuracy: By standardizing procedures and ensuring assay reliability, CAP guidelines contribute to more accurate diagnoses.
Enhance Patient Safety: Accurate diagnoses lead to more appropriate treatment decisions, ultimately improving patient outcomes.
Meet Accreditation Requirements: Although not all recommendations are explicitly required, adherence to CAP guidelines can facilitate compliance with accreditation standards.
Promote Continuous Improvement: The CAP guidelines are regularly reviewed and updated, encouraging laboratories to stay current with the latest advancements in pathology and laboratory medicine.

Read also: About Grossmont Community College

tags: #college #of #american #pathologists #guidelines